Caregivers of individuals with Dravet or Lennox-Gastaut syndrome reported CBD benefits extending beyond seizure control, including improvements in behavior, alertness, and quality of life.
Caregivers of epilepsy patients, neurologists, patient advocacy organizations, and families considering CBD treatment.
Beyond seizuresCaregivers reported CBD benefits in alertness, behavior, cognition, and quality of life beyond seizure control
What the researchers found
Qualitative interviews with caregivers revealed that CBD treatment produced meaningful benefits beyond seizure reduction, including improvements in alertness, behavior, cognition, and overall quality of life for individuals with Dravet and Lennox-Gastaut syndromes.
Why it matters
Clinical trials focus on seizure frequency, but caregivers care about broader quality of life. Understanding these additional benefits helps justify CBD treatment and set realistic expectations.
The numbers in context
Multinational qualitative study interviewing caregivers of individuals with Dravet syndrome or Lennox-Gastaut syndrome treated with plant-derived CBD.
How the study worked
Multinational qualitative interview study with caregivers of individuals treated with pharmaceutical CBD for Dravet or Lennox-Gastaut syndrome.
Who was studied
Caregivers of individuals with Dravet syndrome or Lennox-Gastaut syndrome receiving CBD treatment across multiple countries.
What this study cannot tell us
Qualitative design cannot establish causation; caregiver reports may be influenced by expectations; no placebo comparison; multinational sample may reflect different healthcare contexts.
How to read the evidence
Qualitative multinational study provides rich caregiver perspectives; not quantitative evidence of non-seizure outcomes.
When this study was published
Recent qualitative study complementing clinical trial data on pharmaceutical CBD.
The bigger picture
This study highlights the importance of patient-reported and caregiver-reported outcomes that clinical trial endpoints may miss, advocating for more holistic evaluation of therapeutic interventions.
Replication
Complements quantitative clinical trial data; qualitative findings consistent across multiple countries.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Which non-seizure benefits are most consistent across patients?
- Do benefits increase over time?
- How do these improvements affect family quality of life?
Read the original research
Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
Journal of child neurology, 38(6-7), 394-406
Citation
Marshall, Jade; Skrobanski, Hanna; Moore-Ramdin, Lisa; Kornalska, Klaudia; Swinburn, Paul; Bowditch, Sally. (2023). Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.. Journal of child neurology, 38(6-7), 394-406. https://doi.org/10.1177/08830738231185241